Saltar al contenido
Merck

917974

Sigma-Aldrich

BocA1V2PF2

Sinónimos:

(S)-2-((S)-1-((S)-2-((S)-2-((tert-Butoxycarbonyl)amino)propanamido)-2-cyclohexylacetyl)pyrrolidine-2-carboxamido)-3-(4-fluorophenyl)propanoic acid, IAP E3 ligase lead for protein degrader research, SNIPER building block

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización


About This Item

Fórmula empírica (notación de Hill):
C30H43FN4O7
Peso molecular:
590.68
UNSPSC Code:
41116105
NACRES:
NA.22

ligand

BocA1V2PF2

Quality Level

form

powder

reaction suitability

reagent type: ligand

functional group

carboxylic acid

storage temp.

2-8°C

SMILES string

C[C@H](NC(OC(C)(C)C)=O)C(N[C@H](C(N1CCC[C@H]1C(N[C@H](C(O)=O)CC2=CC=C(C=C2)F)=O)=O)C3CCCCC3)=O

Application

BocA1V2PF2 is an in silico-derived inhibitor of apoptosis protein (IAP)-recruiting ligand for targeted protein degradation and SNIPER (specific and non-genetic IAP-dependent protein erasers) development, launched in partnership with ComInnex. Learn more about the novel IAP ligands generated through virtual screening of AVP mimetics in our Technology Spotlights. A C-terminal variant of BocA1V2PF2 is also available as A1V2PF2-NHEt (916714).

BocA1V2PF2 conjugates are also available for degrader synthesis. Browse our full synthesis offering here for streamlining
SNIPER and PROTAC® degrader libraries: Degrader Building Blocks

917443BocA1V2PF2-NHC6-NH2
917699 BocA1V2PF2-NHC10-NH2
917958 BocA1V2PF2-NHPEG1-NH2
916692 BocA1V2PF2-NHPEG3-NH2

Legal Information

PROTAC is a registered trademark of Arvinas Operations, Inc., and is used under license

related product

Referencia del producto
Descripción
Precios

Storage Class

11 - Combustible Solids

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable


Certificados de análisis (COA)

Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Mikihiko Naito et al.
Drug discovery today. Technologies, 31, 35-42 (2019-06-16)
The induction of protein degradation by chimeric small molecules represented by proteolysis-targeting chimeras (PROTACs) is an emerging approach for novel drug development. We have developed a series of chimeric molecules termed specific and non-genetic inhibitor of apoptosis protein (IAP)-dependent protein
Nobumichi Ohoka et al.
The Journal of biological chemistry, 292(11), 4556-4570 (2017-02-06)
Many diseases, especially cancers, result from aberrant or overexpression of pathogenic proteins. Specific inhibitors against these proteins have shown remarkable therapeutic effects, but these are limited mainly to enzymes. An alternative approach that may have utility in drug development relies
Tasuku Ishida et al.
SLAS discovery : advancing life sciences R & D, 26(4), 484-502 (2020-11-05)
Bifunctional degrader molecules, also called proteolysis-targeting chimeras (PROTACs), are a new modality of chemical tools and potential therapeutics to understand and treat human disease. A required PROTAC component is a ligand binding to an E3 ubiquitin ligase, which is then joined to another ligand binding to a protein to

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico